Letter to the Editor
To the Editor:
We are writing to you regarding the article referenced above by Van Rossum and Holsopple, "Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options," 1 because we believe that the article does not currently comply with Hospital Pharmacy's dedication to "the promotion of best practices and medication safety." 2 The article contains several inaccuracies regarding the epidemiology of Gaucher disease, the available evidence regarding treatment, and the approved indications for substrate reduction therapies. These errors could mislead providers in regard to the proper management of Gaucher disease.
First, " Table 1 : Gaucher disease characteristics by condition type" contains several statements that are not in line with current evidence. In the section "Prevalence/Incidence," the statements under type 2 and type 3 disease are outdated. While only 1% to 5% of patients in the United States, Europe, and Israel are diagnosed with type 2 or type 3 disease, it is now known that at least one-third of patients diagnosed in other regions have a type 2 or type 3 phenotype. 3 Under "Mutation Type," the phrase"N370S genotype mutation" would be better worded as "at least one N370S allele," as many patients with type 1 Gaucher disease are N370S/L444P or N370S/Other heterozygotes. 4 In the section "Age at Diagnosis," the statement "typically presents in adolescence" would be better phrased as "typically presents in childhood or adolescence" as a majority of patients are diagnosed before 10 years of age. 4 Finally, the entry for type 1 in the "Life Expectancy" that states "normal to near normal" is false. Published data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry similar to a preenzyme replacement therapy cohort found that life span was reduced by approximately 9 years. 5 Second, in the "Results and Discussion" section under "Treatment Goals," the statement "The goal when initiating therapy is to achieve long-term therapeutic targets within 1 to 2 years of therapy initiation" is not correct. Several goals, including improvement in platelet counts in patients with severe baseline thrombocytopenia, reduction in liver volume, reduction in spleen volume, and improvement in trabecular bone mineral density (BMD), have targets of up to 5 years. 6 Third, under "Enzyme Replacement Therapy," the statement "Both taliglucerase alfa and velaglucerase alfa have a lower incidence of antibody development than imiglucerase" is incorrect. There have been no head-to-head studies testing the three therapies using the same assay methodologies. Because of this, the velaglucerase alfa (VPRIV) label and the taliglucerase (ELELYSO) label state "comparison of the incidence of antibodies to [this product] with the incidence of antibodies to other products may be misleading." 7, 8 Furthermore, the assertion that "taliglucerase alfa may have an improved safety profile compared with imiglucerase and velaglucerase alfa" is misrepresentative. All three products' labels contain warnings regarding immunogenic reactions, including the risk of hypersensitivity and reported cases of anaphylaxis. [7] [8] [9] Fourth, the assertion that "data on the use of imiglucerase in pregnant humans are lacking" is false. There have been numerous publications reporting outcomes from using imiglucerase during pregnancy. [10] [11] [12] [13] Also, based on reported outcomes from 150 pregnancies, the European Medicines Agency recommends that "treatment naïve women should be advised to consider commencing therapy prior to conception [and] , in women receiving Cerezyme, treatment continuation throughout pregnancy should be considered." 14 Fifth, in " Table 2 : Comparison of FDA-approved enzyme replacement therapies," the entry for velaglucerase alfa in the "Source" section that reads "recombinant DNA technology in human fibroblasts cells" is misleading, as velaglucerase is produced in a human fibrosarcoma cell line. 15 Also, the entry under "Dosing" for imiglucerase only lists the potential dose range but does not include the label's recommendation that the "dosage should be individualized to each patient." 9 Furthermore, the entries under "Pregnancy Category" are incomplete due to not citing evidence related to pregnancy outcomes in treated patients as noted above.
Sixth, under "Substrate Reduction Therapy," the authors erroneously state that substrate reduction therapies are "another option" for "patients who cannot tolerate enzyme replacement therapy or experience anaphylactic reactions." While this description is aligned with miglustat's label, it does not apply to eliglustat, which is approved as a first-line therapy for type 1 Gaucher disease. 16, 17 Eliglustat's efficacy in treatment-naive patients was demonstrated in the Phase 3 ENGAGE trial (NCT00891202), which is not cited in this article's "Eliglustat Efficacy" section. 18 In addition to this, the authors state that comparisons between enzyme replacement therapy and substrate reduction therapy are limited, despite the fact that the Phase 3 ENCORE trial (NCT00943111) demonstrated noninferiority in patients switched from imiglucerase to eliglustat, as cited elsewhere in the article. 19 It should also be noted that, since the publication of this review, data from the ENCORE long-term extension have been released and found that patients remained stable on eliglustat for up to 4 years of follow-up. 20 Finally, the authors caution that "patients who are ultra-rapid CYP2D6 metabolizers are not good candidates for eliglustat," but do not mention that ultra-metabolizers account for 2% to 5% of the population, a distribution that was mirrored in eliglustat's clinical trial population. 21, 22 In total, these statements mischaracterize the proportion of patients that may benefit from eliglustat.
Finally, in both the abstract and conclusion, the authors note that "there are no approved therapies for type 2 and type 3 disease." In fact, taliglucerase is approved in Canada for "the hematological manifestations in pediatric patients with a confirmed diagnosis of type 3 Gaucher disease." 23 Also, imiglucerase is approved for nonneurological manifestations of type 3 disease in the European Union due to it having effects beyond "symptom management," including improvement in anemia, thrombocytopenia, bone disease, and visceromegaly demonstrated in multiple studies. 14, 24 In summary, we respectfully request that your readership be made aware of the inaccuracies and limitations described above.
